focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
With the potential of significant news flow from the company and when you consider the constant news flow from the majors, latest $240 bill Novartis about to be spinning off Sandoz and concentrate on clever medicine such as Precision Oncology, well Avacta is soon to be the hottest company in town and be seriously re-rated.
Meanwhile last hour or so, buy/sell ratio is certainly moving forward and the buyers are quite rightly getting ready for next week with Cohort results/ more noise from the majors and M&A in the hottest area in oncology: Precision Oncology! !
Preparing for US listing sooner rather than later with well known cornerstone investors on board. Excellent defensive action vs a take over.Similar to what Arm Holdings is doing.
Remember the Ceo once commented during a Q&A regarding valuation of the AVA pipeline, “ well you might as well apply $1 billion to each AVA”.